{"id":166479,"date":"2019-08-26T10:44:05","date_gmt":"2019-08-26T10:44:05","guid":{"rendered":"http:\/\/www.georgianewsdesk.com\/news\/story\/166479\/creative-biolabs-releases-endtoend-car-hybrid-tcrt-cell-therapy-development-services.html"},"modified":"2019-08-26T10:44:05","modified_gmt":"2019-08-26T10:44:05","slug":"creative-biolabs-releases-endtoend-car-hybrid-tcrt-cell-therapy-development-services","status":"publish","type":"post","link":"http:\/\/www.honolulunewsnow.com\/news\/story\/166479\/creative-biolabs-releases-endtoend-car-hybrid-tcrt-cell-therapy-development-services.html","title":{"rendered":"Creative Biolabs Releases End-to-end CAR Hybrid TCR-T Cell Therapy Development Services"},"content":{"rendered":"
Based on a well-established TCR and CAR T&NK cell immune therapy development platform, Creative Biolabs, a rich-experienced global contract research organization, releases a brand new end-to-end CAR hybrid TCR-T cell therapy development services.<\/div>\n

New York, US – August 26, 2019 –<\/strong> Chimeric Antigen Receptor (CAR) and T Cell Receptor (TCR) cell therapy are two most popular immune therapies that accelerate the drug discovery and development process for the treatment of various diseases, especially cancers, which utilize immune cells in human body to identify, locate and finally kill tumor cells, achieving the transformation from basic immune research to clinical trials. The CAR Hybrid TCR-T (CHyT-T) cell therapy development platform in Creative Biolabs integrates the unique advantages of TCR-T and CAR-T cell therapy<\/a>, and overcomes their limitations, eventually powering T cells for cancer cures.<\/p>\n

“As a novel engineered T cell therapy developed by our seasoned scientists, the CHyT is capable of participating in the whole TCR process to fully activate T cells by conjugating the specific tumor antigen to the TCR complex via high-affinity scFv which can recognize the antigens on tumor cells without HLA dependence, thereby fully activating T cells and completing a powerful and consistent tumor attack.” – Introduced by the senior scientist of Creative Biolabs.<\/p>\n

“According to the properties of our clients’ project, our technicians will propose the most appropriate solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence by unrivaled, proprietary drug design, study data, product candidate, advanced project lifecycle management, as well as real-time data.”<\/p>\n

The end-to-end solutions to CAR Hybrid TCR-T Cell Therapy<\/a> include:<\/p>\n